Florham Park, NJ, March 25, 2021

 Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, today announced the launch of Omeprazole Delayed Release Capsules, 20mg, generic to Prilosec®.

 “Xiromed is committed to providing cost effective generic products to our customers, and the launch of Omeprazole Delayed Release Capsules is the latest example of that commitment.  We continue to be focused on expanding our portfolio and offering new products in a variety of dosage forms,” commented Xiromed CEO, Narasimhan Mani.

Prilosec® is a proton pump inhibitor indicated for the treatment in adults of duodenal ulcer and gastric ulcer and the treatment in adults and children of gastroesophageal reflux disease (GERD) and maintenance of healing of erosive esophagitis.  Annual market sales for Prilosec® Delayed Release Capsules, 20mg and its generics for the twelve month period ending January, 2021 were $104.5 million, according to IQVIA™.  

 Xiromed LLC, located in Florham Park, NJ, is the US generic division of Insud Pharma, S.L., a global pharmaceutical group headquartered in Madrid, Spain.  Xiromed is focused on developing and commercializing high quality generic pharmaceutical products for the US market.  In addition to its commercial portfolio of generics available in the US, Xiromed has a robust development portfolio of generic pharmaceutical products in various stages of development, including injectable, inhalation and complex generic products.  Learn more at http://www.xiromed.com/usa/